ArticleNew microbes and new infections2026
Deciphering the genotypic profiles of Carbapenem-resistant Enterobacterales: A study from a tertiary care hospital in Bihar, India.
Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Enterobacterales (CRE) present a critical challenge in healthcare, especially in low-resource settings, due to limited treatment options and high mortality rates. The global prevalence of CRE is on the rise, necessitating comprehensive understanding and strategies to combat this threat. Data on carbapenemase gene distribution among CRE from eastern India remain scarce. Objectives: To characterize the distribution of carbapenemase genes among CRE isolates from a tertiary care hospital in Bihar, India, and to assess their correlation with phenotypic resistance patterns. Methods: Hospital-based cross-sectional study was conducted from July 2021 to July 2023 at a tertiary healthcare centre in Bihar, India. Phenotypic methods included mCIM, eCIM, and carbapenemase inhibition assays. Genotypic analysis employed multiplex PCR to detect blaNDM, blaIMP, blaVIM, blaKPC, and blaOXA-48. PCR products were visualised by gel electrophoresis. Descriptive analyses were used to summarize genotypic and phenotypic findings. Statistical analysis was performed using SPSS v.23. Results: Among the 98 isolates subjected to multiplex PCR-based carbapenemase gene profiling Conclusions: High blaNDM prevalence in Bihar's CRE isolates necessitates urgent surveillance and strict infection control. Recommended therapies include Cefiderocol or Ceftazidime-avibactam plus Aztreonam. Continued molecular research and diagnostic enhancements remain critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.